Acute Erythroid Leukemia - 171 Studies Found
| Active, not recruiting |
: Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia :
: |
| Withdrawn |
: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|
| Completed |
: Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes :
|
| Active, not recruiting |
: Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia :
: |
| Completed |
: Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
: |
| Terminated |
: Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS :
: |
| Completed |
: Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia :
|
| Terminated |
: Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia :
|
| Terminated |
: Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy :
: |
| Terminated |
: Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|